Galapagos, Cancer Research collaborate on new anti-cancer drug discovery

By E. Janene Geiss

Philadelphia, Jan. 19 - Galapagos NV and Cancer Research Technology announced that they have entered into a new collaboration in anti-cancer drug discovery research.

Under terms of the agreement, Galapagos' service division, BioFocus, will perform medicinal chemistry services on a series of Cancer Research anti-cancer drug programs, according to a company news release.

In return, Cancer Research will fund the work of four BioFocus scientists throughout 2006, officials said.

"This agreement testifies to the high quality of BioFocus' medicinal chemistry expertise and the overall competitiveness of our integrated services portfolio," Onno van de Stolpe, chief executive officer of Galapagos, said in the release.

The collaboration will ensure Cancer Research's programs advance rapidly through early stage development, creating robust licensing opportunities and cancer-patient benefit, officials said.

Galapagos, based in Mechelen, Belgium, is a genomics-based pharmaceutical company with programs based on proprietary, novel targets in the bone and joint diseases - osteoarthritis, osteoporosis and rheumatoid arthritis.

Cancer Research is a wholly owned company of Cancer Research UK, a London-based pharmaceutical company with a focus on oncology drug discovery and commercialization.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.